Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Breast Cancer

Free Subscription 04.06.2018 1 Ann Surg 2 Ann Surg Oncol 5 Anticancer Res 5 BMC Cancer 2 Br J Cancer 5 Breast Cancer 7 Breast Cancer Res Treat 1 Cancer Cell 1 Cancer Lett 1 Cancer Res 1 Carcinogenesis 3 Clin Breast Cancer 3 Clin Cancer Res 1 Clin Exp Metastasis 3 Eur J Surg Oncol 1 Eur Radiol 1 Gene 1 J Clin Oncol 4 Lancet Oncol 1 Mod Pathol 2 NPJ Breast Cancer 2 Oncogene 2 Oncology 2 Oncology (Williston Park) 6 PLoS One

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Ann Surg

1. OZMEN T, Lazaro M, Zhou Y, Vinyard A, et al
   Evaluation of Simplified Lymphatic Microsurgical Preventing Healing Approach (S-LYMPHA) for the Prevention of Breast Cancer-Related Clinical Lymphedema After Axillary Lymph Node Dissection.
   Ann Surg. 2018 May 23. doi: 10.1097/SLA.0000000000002827.
   PubMed     Text format     Abstract available
   
   

   
   Ann Surg Oncol

2. MOOSSDORFF M, Nakhlis F, Hu J, Barry WT, et al
   The Potential Impact of AMAROS on the Management of the Axilla in Patients with Clinical T1-2N0 Breast Cancer Undergoing Primary Total Mastectomy.
   Ann Surg Oncol. 2018 May 31. pii: 10.1245/s10434-018-6519.
   PubMed     Text format     Abstract available
   
   
3. ONG CT, Campbell BM, Thomas SM, Greenup RA, et al
   Metaplastic Breast Cancer Treatment and Outcomes in 2500 Patients: A Retrospective Analysis of a National Oncology Database.
   Ann Surg Oncol. 2018 May 31. pii: 10.1245/s10434-018-6533.
   PubMed     Text format     Abstract available
   
   

   
   Anticancer Res

4. DANDAMUDI A, Tommie J, Nommsen-Rivers L, Couch S, et al
   Dietary Patterns and Breast Cancer Risk: A Systematic Review.
   Anticancer Res. 2018;38:3209-3222.
   PubMed     Text format     Abstract available
   
   
5. CHOE MH, Kim J, Ahn J, Hwang SG, et al
   Centrosome Clustering Is a Tumor-selective Target for the Improvement of Radiotherapy in Breast Cancer Cells.
   Anticancer Res. 2018;38:3393-3400.
   PubMed     Text format     Abstract available
   
   
6. LI J, Zhang J, Jin L, Deng H, et al
   Silencing lnc-ASAH2B-2 Inhibits Breast Cancer Cell Growth via the mTOR Pathway.
   Anticancer Res. 2018;38:3427-3434.
   PubMed     Text format     Abstract available
   
   
7. TRESKA V, Topolcan O, Zoubkova V, Treskova I, et al
   Perioperative Tumour Marker Levels as Prognostic Factors for Surgical Treatment of Breast Cancer Liver Metastases.
   Anticancer Res. 2018;38:3647-3652.
   PubMed     Text format     Abstract available
   
   
8. MALTER W, Hellmich M, Badian M, Kirn V, et al
   Factors Predictive of Sentinel Lymph Node Involvement in Primary Breast Cancer.
   Anticancer Res. 2018;38:3657-3662.
   PubMed     Text format     Abstract available
   
   

   
   BMC Cancer

9. NATTENMULLER CJ, Kriegsmann M, Sookthai D, Fortner RT, et al
   Obesity as risk factor for subtypes of breast cancer: results from a prospective cohort study.
   BMC Cancer. 2018;18:616.
   PubMed     Text format     Abstract available
   
   
10. MUDDUWA L, Peiris H, Gunasekara S, Abeysiriwardhana D, et al
    KIBRA; a novel biomarker predicting recurrence free survival of breast cancer patients receiving adjuvant therapy.
    BMC Cancer. 2018;18:589.
    PubMed     Text format     Abstract available
    
    
11. HOUSE CD, Grajales V, Ozaki M, Jordan E, et al
    IKappaKappaepsilon cooperates with either MEK or non-canonical NF-kB driving growth of triple-negative breast cancer cells in different contexts.
    BMC Cancer. 2018;18:595.
    PubMed     Text format     Abstract available
    
    
12. MADHU KRISHNA B, Chaudhary S, Mishra DR, Naik SK, et al
    Estrogen receptor alpha dependent regulation of estrogen related receptor beta and its role in cell cycle in breast cancer.
    BMC Cancer. 2018;18:607.
    PubMed     Text format     Abstract available
    
    
13. WHITNEY J, Corredor G, Janowczyk A, Ganesan S, et al
    Quantitative nuclear histomorphometry predicts oncotype DX risk categories for early stage ER+ breast cancer.
    BMC Cancer. 2018;18:610.
    PubMed     Text format     Abstract available
    
    

    
    Br J Cancer

14. WEIN L, Luen SJ, Savas P, Salgado R, et al
    Checkpoint blockade in the treatment of breast cancer: current status and future directions.
    Br J Cancer. 2018 May 29. pii: 10.1038/s41416-018-0126.
    PubMed     Text format     Abstract available
    
    
15. HALKETT G, O'Connor M, Jefford M, Aranda S, et al
    RT Prepare: a radiation therapist-delivered intervention reduces psychological distress in women with breast cancer referred for radiotherapy.
    Br J Cancer. 2018 Jun 1. pii: 10.1038/s41416-018-0112.
    PubMed     Text format     Abstract available
    
    

    
    Breast Cancer

16. LOUHICHI T, Ziadi S, Saad H, Dhiab MB, et al
    Clinicopathological significance of cancer stem cell markers CD44 and ALDH1 expression in breast cancer.
    Breast Cancer. 2018 May 29. pii: 10.1007/s12282-018-0875.
    PubMed     Text format     Abstract available
    
    
17. SAJI S
    The long and winding road for overcoming resistance to hormone therapy in breast cancer.
    Breast Cancer. 2018 May 28. pii: 10.1007/s12282-018-0876.
    PubMed     Text format    
    
    
18. GAO L, Li SC
    Cost-effectiveness analysis of lipegfilgrastim as primary prophylaxis in women with breast cancer in Australia: a modelled economic evaluation.
    Breast Cancer. 2018 May 25. pii: 10.1007/s12282-018-0872.
    PubMed     Text format     Abstract available
    
    
19. WEN L, Liu L, Wen L, Yu T, et al
    Artesunate promotes G2/M cell cycle arrest in MCF7 breast cancer cells through ATM activation.
    Breast Cancer. 2018 May 24. pii: 10.1007/s12282-018-0873.
    PubMed     Text format     Abstract available
    
    
20. OSTAPCHUK YO, Perfilyeva YV, Kustova EA, Urazalieva NT, et al
    Functional heterogeneity of circulating T regulatory cell subsets in breast cancer patients.
    Breast Cancer. 2018 May 24. pii: 10.1007/s12282-018-0874.
    PubMed     Text format     Abstract available
    
    

    
    Breast Cancer Res Treat

21. LIU J, Yang Y, Wang H, Wang B, et al
    Syntenin1/MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1.
    Breast Cancer Res Treat. 2018 May 29. pii: 10.1007/s10549-018-4833.
    PubMed     Text format     Abstract available
    
    
22. JAIN S, Shah AN, Santa-Maria CA, Siziopikou K, et al
    Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy.
    Breast Cancer Res Treat. 2018 May 30. pii: 10.1007/s10549-018-4792.
    PubMed     Text format     Abstract available
    
    
23. JACOB L, Scholten PC, Kostev K, Kalder M, et al
    Association between sleep disorders and the presence of breast cancer metastases in gynecological practices in Germany: a case-control study of 11,412 women.
    Breast Cancer Res Treat. 2018 May 29. pii: 10.1007/s10549-018-4831.
    PubMed     Text format     Abstract available
    
    
24. LEOPOLD C, Wagner AK, Zhang F, Lu CY, et al
    Total and out-of-pocket expenditures among women with metastatic breast cancer in low-deductible versus high-deductible health plans.
    Breast Cancer Res Treat. 2018 Jun 1. pii: 10.1007/s10549-018-4819.
    PubMed     Text format     Abstract available
    
    
25. WANG Z, Katsaros D, Biglia N, Shen Y, et al
    High expression of long non-coding RNA MALAT1 in breast cancer is associated with poor relapse-free survival.
    Breast Cancer Res Treat. 2018 May 29. pii: 10.1007/s10549-018-4839.
    PubMed     Text format     Abstract available
    
    
26. ELMI M, Sequeira S, Azin A, Elnahas A, et al
    Evolving surgical treatment decisions for male breast cancer: an analysis of the National Surgical Quality Improvement Program (NSQIP) database.
    Breast Cancer Res Treat. 2018 May 28. pii: 10.1007/s10549-018-4830.
    PubMed     Text format     Abstract available
    
    
27. ANDERSSON Y, Bergkvist L, Frisell J, de Boniface J, et al
    Long-term breast cancer survival in relation to the metastatic tumor burden in axillary lymph nodes.
    Breast Cancer Res Treat. 2018 May 30. pii: 10.1007/s10549-018-4820.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Cell

28. CANOVAS B, Igea A, Sartori AA, Gomis RR, et al
    Targeting p38alpha Increases DNA Damage, Chromosome Instability, and the Anti-tumoral Response to Taxanes in Breast Cancer Cells.
    Cancer Cell. 2018 May 14. pii: S1535-6108(18)30181.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Lett

29. WU J, Jiang Z, Chen C, Hu Q, et al
    CircIRAK3 sponges miR-3607 to facilitate breast cancer metastasis.
    Cancer Lett. 2018;430:179-192.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Res

30. JASTRZEBSKI K, Thijssen B, Kluin RJ, de Lint K, et al
    Integrative modeling identifies key determinants of inhibitor sensitivity in breast cancer cell lines.
    Cancer Res. 2018 May 29. pii: 0008-5472.CAN-17-2698.
    PubMed     Text format     Abstract available
    
    

    
    Carcinogenesis

31. BAK MJ, Furmanski P, Shan NL, Lee HJ, et al
    Tocopherols inhibit estrogen-induced cancer stemness and OCT4 signaling in breast cancer.
    Carcinogenesis. 2018 May 26. pii: 5004853. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    

    
    Clin Breast Cancer

32. KIM HJ, Lee MH, Lee JE, Park S, et al
    Oncologic Safety of Gonadotropin-Releasing Hormone Agonist for Ovarian Function Protection During Breast Cancer Chemotherapy.
    Clin Breast Cancer. 2018 Apr 19. pii: S1526-8209(18)30019.
    PubMed     Text format     Abstract available
    
    
33. DENG Y, Ma G, Li W, Wang T, et al
    CDK4/6 Inhibitors in Combination With Hormone Therapy for HR(+)/HER2(-) Advanced Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Clin Breast Cancer. 2018 May 4. pii: S1526-8209(17)30798.
    PubMed     Text format     Abstract available
    
    
34. KOZAK MM, Jacobson CE, von Eyben R, Walck E, et al
    Patterns of Distant Failure by Intrinsic Breast Cancer Subtype in Premenopausal Women Treated With Neoadjuvant Chemotherapy.
    Clin Breast Cancer. 2018 May 7. pii: S1526-8209(17)30796.
    PubMed     Text format     Abstract available
    
    

    
    Clin Cancer Res

35. ANURAG M, Punturi N, Hoog J, Bainbridge MN, et al
    Comprehensive profiling of DNA repair defects in breast cancer identifies a novel class of endocrine therapy resistance drivers.
    Clin Cancer Res. 2018 May 23. pii: 1078-0432.CCR-17-3702.
    PubMed     Text format     Abstract available
    
    
36. UNNI N, Sudhan DR, Arteaga CL
    Neratinib: Inching up on the cure rate of HER2+ breast cancer?
    Clin Cancer Res. 2018 May 25. pii: 1078-0432.CCR-18-1114.
    PubMed     Text format     Abstract available
    
    
37. DICKLER MN, Saura C, Richards D, Krop I, et al
    Phase II Study of Taselisib (GDC0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer.
    Clin Cancer Res. 2018 May 23. pii: 1078-0432.CCR-18-0613.
    PubMed     Text format     Abstract available
    
    

    
    Clin Exp Metastasis

38. NATHANSON SD, Krag D, Kuerer HM, Newman LA, et al
    Breast cancer metastasis through the lympho-vascular system.
    Clin Exp Metastasis. 2018 May 23. pii: 10.1007/s10585-018-9902.
    PubMed     Text format     Abstract available
    
    

    
    Eur J Surg Oncol

39. PAPALOUKA V, Gilbert FJ
    Inflammatory breast cancer-importance of breast imaging.
    Eur J Surg Oncol. 2018 May 16. pii: S0748-7983(18)31058.
    PubMed     Text format    
    
    
40. FENTIMAN IS
    Unmet needs of men with breast cancer.
    Eur J Surg Oncol. 2018 May 15. pii: S0748-7983(18)31054.
    PubMed     Text format     Abstract available
    
    
41. ORECCHIA R
    Radiation therapy for inflammatory breast cancer.
    Eur J Surg Oncol. 2018 May 17. pii: S0748-7983(18)31069.
    PubMed     Text format     Abstract available
    
    

    
    Eur Radiol

42. MALL S, Noakes J, Kossoff M, Lee W, et al
    Can digital breast tomosynthesis perform better than standard digital mammography work-up in breast cancer assessment clinic?
    Eur Radiol. 2018 May 30. pii: 10.1007/s00330-018-5473.
    PubMed     Text format     Abstract available
    
    

    
    Gene

43. XU J, Zhang W, Tang L, Chen W, et al
    Epithelial-mesenchymal transition induced PAI-1 is associated with prognosis of triple-negative breast cancer patients.
    Gene. 2018 May 23. pii: S0378-1119(18)30586-9. doi: 10.1016/j.gene.2018.
    PubMed     Text format     Abstract available
    
    

    
    J Clin Oncol

44. WOLFF AC, Hammond MEH, Allison KH, Harvey BE, et al
    Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.
    J Clin Oncol. 2018 May 30:JCO2018778738. doi: 10.1200/JCO.2018.77.8738.
    PubMed     Text format     Abstract available
    
    

    
    Lancet Oncol

45. MURTHY R, Borges VF, Conlin A, Chaves J, et al
    Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study.
    Lancet Oncol. 2018 May 24. pii: S1470-2045(18)30256.
    PubMed     Text format     Abstract available
    
    
46. FOUKAKIS T
    Ribociclib in premenopausal women with advanced breast cancer.
    Lancet Oncol. 2018 May 24. pii: S1470-2045(18)30367.
    PubMed     Text format    
    
    
47. TRIPATHY D, Im SA, Colleoni M, Franke F, et al
    Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
    Lancet Oncol. 2018 May 24. pii: S1470-2045(18)30292.
    PubMed     Text format     Abstract available
    
    
48. BURKI TK
    Responses to carboplatin in BRCA1/2-mutated breast cancer.
    Lancet Oncol. 2018 May 24. pii: S1470-2045(18)30407.
    PubMed     Text format    
    
    

    
    Mod Pathol

49. DILL EA, Dillon PM, Bullock TN, Mills AM, et al
    IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1.
    Mod Pathol. 2018 May 25. pii: 10.1038/s41379-018-0061.
    PubMed     Text format     Abstract available
    
    

    
    NPJ Breast Cancer

50. SPARANO JA
    Prognostic gene expression assays in breast cancer: are two better than one?
    NPJ Breast Cancer. 2018;4:11.
    PubMed     Text format    
    
    
51. CARDOSO F, Curigliano G
    The PROMISe to increase precision in adjuvant therapy for early breast cancer: To "Type" or to "Print"?
    NPJ Breast Cancer. 2018;4:12.
    PubMed     Text format    
    
    

    
    Oncogene

52. SIRINIAN C, Papanastasiou AD, Schizas M, Spella M, et al
    RANK-c attenuates aggressive properties of ER-negative breast cancer by inhibiting NF-kappaB activation and EGFR signaling.
    Oncogene. 2018 May 29. pii: 10.1038/s41388-018-0324.
    PubMed     Text format     Abstract available
    
    
53. LU L, Dong J, Wang L, Xia Q, et al
    Activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote radioresistance in breast cancer and overcome of radioresistance with niclosamide.
    Oncogene. 2018 May 31. pii: 10.1038/s41388-018-0340.
    PubMed     Text format     Abstract available
    
    

    
    Oncology

54. LANDRY S, Chasles G, Pointreau Y, Bourgeois H, et al
    Influence of an Adapted Physical Activity Program on Self-Esteem and Quality of Life of Breast Cancer Patients after Mastectomy.
    Oncology. 2018 May 30:1-4. doi: 10.1159/000489265.
    PubMed     Text format     Abstract available
    
    
55. CORSO G, Maisonneuve P, Santomauro GI, De Scalzi AM, et al
    Ipsilateral Breast Tumor Reappearance and Contralateral Breast Cancer after Primary Breast Cancer Treatment: A Comprehensive Retrospective Study of 15,168 Patients.
    Oncology. 2018 May 30:1-9. doi: 10.1159/000488764.
    PubMed     Text format     Abstract available
    
    

    
    Oncology (Williston Park)

56. SHAH M, Nunes MR, Stearns V
    CDK4/6 Inhibitors: Game Changers in the Management of Hormone Receptor-Positive Advanced Breast Cancer?
    Oncology (Williston Park). 2018;32:216-22.
    PubMed     Text format     Abstract available
    
    
57. BROCKWAY JP, Shapiro CL
    Improving Adherence to Endocrine Therapy in Women With HR-Positive Breast Cancer.
    Oncology (Williston Park). 2018;32:235-7.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

58. RAINEY L, van der Waal D, Donnelly LS, Evans DG, et al
    Women's decision-making regarding risk-stratified breast cancer screening and prevention from the perspective of international healthcare professionals.
    PLoS One. 2018;13:e0197772.
    PubMed     Text format     Abstract available
    
    
59. HARALDSDOTTIR A, Torfadottir JE, Valdimarsdottir UA, Adami HO, et al
    Dietary habits in adolescence and midlife and risk of breast cancer in older women.
    PLoS One. 2018;13:e0198017.
    PubMed     Text format     Abstract available
    
    
60. GHOSH A, Sarkar S, Banerjee S, Behbod F, et al
    MIND model for triple-negative breast cancer in syngeneic mice for quick and sequential progression analysis of lung metastasis.
    PLoS One. 2018;13:e0198143.
    PubMed     Text format     Abstract available
    
    
61. VEYS I, Pop CF, Barbieux R, Moreau M, et al
    ICG fluorescence imaging as a new tool for optimization of pathological evaluation in breast cancer tumors after neoadjuvant chemotherapy.
    PLoS One. 2018;13:e0197857.
    PubMed     Text format     Abstract available
    
    
62. ALHAMAMI M, Cheng W, Lyu Y, Allen C, et al
    Manganese-porphyrin-enhanced MRI for the detection of cancer cells: A quantitative in vitro investigation with multiple clinical subtypes of breast cancer.
    PLoS One. 2018;13:e0196998.
    PubMed     Text format     Abstract available
    
    
63. CRUZ-ROA A, Gilmore H, Basavanhally A, Feldman M, et al
    High-throughput adaptive sampling for whole-slide histopathology image analysis (HASHI) via convolutional neural networks: Application to invasive breast cancer detection.
    PLoS One. 2018;13:e0196828.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: